ES2600789T3 - Tratamiento de infecciones por VIH-1 latentes usando auranofina o trióxido de arsénico - Google Patents

Tratamiento de infecciones por VIH-1 latentes usando auranofina o trióxido de arsénico Download PDF

Info

Publication number
ES2600789T3
ES2600789T3 ES09759664.7T ES09759664T ES2600789T3 ES 2600789 T3 ES2600789 T3 ES 2600789T3 ES 09759664 T ES09759664 T ES 09759664T ES 2600789 T3 ES2600789 T3 ES 2600789T3
Authority
ES
Spain
Prior art keywords
hiv
cells
auranofin
hdaci
treatment
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Active
Application number
ES09759664.7T
Other languages
English (en)
Spanish (es)
Inventor
Andrea Savarino
Marina Lusic
Antonello Mai
Anna Teresa Palamara
Enrico Garaci
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
St Superiore Di Sanita
Istituto Superiore di Sanità
Original Assignee
St Superiore Di Sanita
Istituto Superiore di Sanità
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Priority claimed from GB0819857A external-priority patent/GB0819857D0/en
Priority claimed from GB0908952A external-priority patent/GB0908952D0/en
Application filed by St Superiore Di Sanita, Istituto Superiore di Sanità filed Critical St Superiore Di Sanita
Application granted granted Critical
Publication of ES2600789T3 publication Critical patent/ES2600789T3/es
Active legal-status Critical Current
Anticipated expiration legal-status Critical

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K33/00—Medicinal preparations containing inorganic active ingredients
    • A61K33/24—Heavy metals; Compounds thereof
    • A61K33/36—Arsenic; Compounds thereof
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/16—Amides, e.g. hydroxamic acids
    • A61K31/165—Amides, e.g. hydroxamic acids having aromatic rings, e.g. colchicine, atenolol, progabide
    • A61K31/167—Amides, e.g. hydroxamic acids having aromatic rings, e.g. colchicine, atenolol, progabide having the nitrogen of a carboxamide group directly attached to the aromatic ring, e.g. lidocaine, paracetamol
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/185—Acids; Anhydrides, halides or salts thereof, e.g. sulfur acids, imidic, hydrazonic or hydroximic acids
    • A61K31/19—Carboxylic acids, e.g. valproic acid
    • A61K31/195—Carboxylic acids, e.g. valproic acid having an amino group
    • A61K31/197—Carboxylic acids, e.g. valproic acid having an amino group the amino and the carboxyl groups being attached to the same acyclic carbon chain, e.g. gamma-aminobutyric acid [GABA], beta-alanine, epsilon-aminocaproic acid or pantothenic acid
    • A61K31/198—Alpha-amino acids, e.g. alanine or edetic acid [EDTA]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/28—Compounds containing heavy metals
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/28—Compounds containing heavy metals
    • A61K31/295—Iron group metal compounds
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/44—Non condensed pyridines; Hydrogenated derivatives thereof
    • A61K31/4406—Non condensed pyridines; Hydrogenated derivatives thereof only substituted in position 3, e.g. zimeldine
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
    • A61K31/505—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim
    • A61K31/513—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim having oxo groups directly attached to the heterocyclic ring, e.g. cytosine
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/555—Heterocyclic compounds containing heavy metals, e.g. hemin, hematin, melarsoprol
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/70—Carbohydrates; Sugars; Derivatives thereof
    • A61K31/7024—Esters of saccharides
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K33/00—Medicinal preparations containing inorganic active ingredients
    • A61K33/04—Sulfur, selenium or tellurium; Compounds thereof
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K33/00—Medicinal preparations containing inorganic active ingredients
    • A61K33/24—Heavy metals; Compounds thereof
    • A61K33/26—Iron; Compounds thereof
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K45/00—Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
    • A61K45/06—Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/12—Antivirals
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/12—Antivirals
    • A61P31/14—Antivirals for RNA viruses
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/12—Antivirals
    • A61P31/14—Antivirals for RNA viruses
    • A61P31/18—Antivirals for RNA viruses for HIV

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Chemical & Material Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • General Health & Medical Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Medicinal Chemistry (AREA)
  • Epidemiology (AREA)
  • Inorganic Chemistry (AREA)
  • Virology (AREA)
  • Molecular Biology (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Organic Chemistry (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Oncology (AREA)
  • Communicable Diseases (AREA)
  • Pain & Pain Management (AREA)
  • AIDS & HIV (AREA)
  • Tropical Medicine & Parasitology (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
ES09759664.7T 2008-10-29 2009-10-29 Tratamiento de infecciones por VIH-1 latentes usando auranofina o trióxido de arsénico Active ES2600789T3 (es)

Applications Claiming Priority (5)

Application Number Priority Date Filing Date Title
GB0819857 2008-10-29
GB0819857A GB0819857D0 (en) 2008-10-29 2008-10-29 Antiviral therapy
GB0908952 2009-05-22
GB0908952A GB0908952D0 (en) 2009-05-22 2009-05-22 Antiviral therapy
PCT/EP2009/007958 WO2010049182A2 (en) 2008-10-29 2009-10-29 Treatment of retroviral reservoirs exploiting oxidative stress

Publications (1)

Publication Number Publication Date
ES2600789T3 true ES2600789T3 (es) 2017-02-10

Family

ID=41596151

Family Applications (1)

Application Number Title Priority Date Filing Date
ES09759664.7T Active ES2600789T3 (es) 2008-10-29 2009-10-29 Tratamiento de infecciones por VIH-1 latentes usando auranofina o trióxido de arsénico

Country Status (6)

Country Link
US (3) US8785493B2 (enExample)
EP (1) EP2349245B1 (enExample)
JP (1) JP5779503B2 (enExample)
ES (1) ES2600789T3 (enExample)
PL (1) PL2349245T3 (enExample)
WO (1) WO2010049182A2 (enExample)

Families Citing this family (15)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
AU2009289649B2 (en) 2008-09-03 2016-05-05 Biomarin Pharmaceutical Inc. Compositions including 6-aminohexanoic acid derivatives as HDAC inhibitors
US9719069B2 (en) 2009-01-27 2017-08-01 University Of Utah Research Foundation Methods and compositions relating to viral latency
GB201011921D0 (en) * 2010-07-15 2010-09-01 Sutan Anwar Method for gas chromatography analysis and maintenance
WO2012118782A1 (en) 2011-02-28 2012-09-07 Repligen Corporation Histone deacetylase inhibitors
US8957066B2 (en) 2011-02-28 2015-02-17 Biomarin Pharmaceutical Inc. Histone deacetylase inhibitors
US10059723B2 (en) 2011-02-28 2018-08-28 Biomarin Pharmaceutical Inc. Histone deacetylase inhibitors
CN102727523A (zh) * 2011-04-02 2012-10-17 复旦大学 一种具有抗hiv潜伏作用的药物及其用途
RU2665554C2 (ru) 2013-03-15 2018-08-31 Байомарин Фармасьютикал Инк. Ингибиторы hdac
EP3008043A2 (en) * 2013-06-14 2016-04-20 University Of Utah Research Foundation Triazol-1-ol analogs anti-retroviral latency drugs
WO2015051035A1 (en) * 2013-10-01 2015-04-09 The J. David Gladstone Institutes Compositions, systems and methods for gene expression noise drug screening and uses thereof
MX393974B (es) * 2016-05-03 2025-03-24 Galera Labs Llc Terapia de combinacion para tratamiento de cancer.
EP3463476A2 (en) 2017-03-23 2019-04-10 Istituto Superiore di Sanità Buthionine sulfoximine and a metallodrug for the treatment of cancer, hiv or a rheumatic disease
US20230285441A1 (en) * 2020-04-15 2023-09-14 Georgia State University Research Foundation, Inc. Treatment of coronavirus infections with auranofin
CN116478070B (zh) * 2022-06-23 2024-09-27 山东第一医科大学(山东省医学科学院) 一种化合物、药物组合物及其在扩张血管或抗病毒领域的应用
CN116947763A (zh) * 2023-07-11 2023-10-27 郑州大学 2-巯基-5-氰基-6-芳基嘧啶杂环类化合物、制备方法和应用

Family Cites Families (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US7232685B2 (en) * 2001-12-19 2007-06-19 The Regents Of The Universtiy Of California Cell lines with latent immunodeficiency virus and methods of use thereof
WO2003053468A1 (en) * 2001-12-21 2003-07-03 Universite Libre De Bruxelles Method for obtaining the elimination of integrated and functional viruses from infected mammal cells
US8247613B2 (en) * 2006-04-17 2012-08-21 The J. David Gladstone Institutes Methods and compositions for the synergistic activation of latent HIV

Also Published As

Publication number Publication date
US8785493B2 (en) 2014-07-22
PL2349245T3 (pl) 2017-07-31
US20170157174A1 (en) 2017-06-08
JP2012506884A (ja) 2012-03-22
JP5779503B2 (ja) 2015-09-16
WO2010049182A3 (en) 2010-12-02
WO2010049182A2 (en) 2010-05-06
EP2349245B1 (en) 2016-08-03
EP2349245A2 (en) 2011-08-03
US20150024065A1 (en) 2015-01-22
US20110305774A1 (en) 2011-12-15

Similar Documents

Publication Publication Date Title
US8785493B2 (en) Treatment of retroviral reservoirs exploiting oxidative stress
US20240390375A1 (en) Methods and compositions for treating viral or virally-induced conditions
Marks et al. Histone deacetylase inhibitors: development as cancer therapy
Pham et al. Research of novel anticancer agents targeting arginase inhibition
CN112920092B (zh) 谷氨酰胺类似物的前药
Saban et al. Hydroxyurea and hydroxamic acid derivatives as antitumor drugs
Duan et al. Design, synthesis, and antitumor evaluation of novel histone deacetylase inhibitors equipped with a phenylsulfonylfuroxan module as a nitric oxide donor
ES2389532T3 (es) Profármacos alquilantes de fosforamidato
CN101374801B (zh) 用于增强抗真菌剂活性的组蛋白脱乙酰酶抑制剂
Ren et al. Epigenetic interventions increase the radiation sensitivity of cancer cells
Takai et al. Human endometrial and ovarian cancer cells: histone deacetylase inhibitors exhibit antiproliferative activity, potently induce cell cycle arrest, and stimulate apoptosis
CN113908159A (zh) 西奥罗尼及其联合用药治疗非霍奇金淋巴瘤的用途
US20160213669A1 (en) Use of n-(4-((3-(2-amino-4-pyrimidinyl)-2-pyridinyl)oxy)phenyl)-4-(4-methyl-2-thienyl)-1-phthalazinamine in combination with histone deacetylase inhibitors for treatment of cancer
JP2022171816A (ja) 患者における転移性癌の有効な治療のための組合せ
EP2297183A1 (en) Treatment for diseases relying on discovery that thioredoxin mediates nitric oxide release in cells
Lech-Maranda et al. Depsipeptide (FK228) as a novel histone deacetylase inhibitor: mechanism of action and anticancer activity
Karam et al. Antitumor activity of the synthetic retinoid ST1926 on primary effusion lymphoma in vitro and in vivo models
de Oliveira et al. Synergistic antiproliferative and pro-apoptotic activity of dacarbazine combined with 2-aminoethyl dihydrogen phosphate in melanoma cells
CN101384301A (zh) 一种治疗流感病毒感染的药物
ES2978336T3 (es) Combinación de un inhibidor de Mcl-1 y midostaurina, usos y composiciones farmacéuticas de la misma
Entin-Meer et al. AN-113, a novel prodrug of 4-phenylbutyrate with increased anti-neoplastic activity in glioma cell lines
Jeon et al. Anticancer effects of the MHY218 novel hydroxamic acid-derived histone deacetylase inhibitor in human ovarian cancer cells
CN112933239A (zh) 激活肿瘤细胞内源性pd-1的试剂在制备抗肿瘤药物中的用途
MXPA06014477A (es) Agente antitumor, fortificador de efecto antitumor y metodo de terapia para cancer.
Kong et al. Design, synthesis and biological evaluation of ALK/HDAC dual-targeting agents